Spironolactone improves lung diffusion in chronic heart failure
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
AIMS: To evaluate whether anti-aldosteronic treatment influences lung diffusion (DLCO) in chronic heart failure (HF) patients. Spironolactone improves clinical conditions and prognosis in chronic HF and reduces connective tissue matrix turnover; DLCO abnormalities in chronic HF are related to increase in fibrosis and connective tissue derangement. METHODS AND RESULTS: Thirty stable chronic HF patients, with reduced DLCO (<80% of predicted), were randomly assigned to active treatment (25 mg spironolactone daily) or placebo in addition to conventional anti-failure treatment. They were evaluated by quality of life questionnaire, laboratory investigations, cardiopulmonary exercise test, and pulmonary function test, which included DLCO and membrane diffusing capacity (DM). The evaluation was done before treatment and 6 months after. Quality of life score and standard pulmonary function tests were not significantly affected by spironolactone, while active treatment increased DLCO due to an increase of DM (DLCO: 18.3+/-3.9 vs. 19.9+/-5.5 mL/min/mmHg; DM: 28.1+/-7.7 vs. 33.3+/-8.6 mL/min/mmHg) and peak oxygen consumption (peak VO2 16.8+/-1.9 vs.18.6+/-2.2 mL/min/kg). Increments of DLCO and peak VO2 were linearly related (R=0.849, P<0.001). CONCLUSION: These data show a positive effect of spironolactone on gas diffusion and exercise capacity suggesting a novel mechanism by which anti-aldosteronic drugs improve HF clinical condition and prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
A new method for detecting anaerobic threshold by gas exchange
Beaver, W. L., Wasserman, K., & Whipp, B. J. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.6.2020 · Cited by 4,103
Anker, S. D., Chua, T. P., Ponikowski, P., Harrington, D., Swan, J. W., Kox, W. J., Poole-Wilson, P. A., & Coats, A. J. S. (1997) · Circulation · doi:10.1161/01.cir.96.2.526 · Cited by 800
Hirasawa, G., Sasano, H., Takahashi, K.-I., Fukushima, K., Suzuki, T., Hiwatashi, N., Toyota, T., Krozowski, Z. S., & Nagura, H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.11.4337 · Cited by 85
Cited by
Mant, J., Doust, J., Roalfe, A., Barton, P., Cowie, M., Glasziou, P., Mant, D., McManus, R., Holder, R., Deeks, J., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13320 · Cited by 498
Heart Failure and cHronic Obstructive Pulmonary Disease: An Ignored Combination?
Rutten, F. H., Cramer, M.-J. M., Lammers, J.-W. J., Grobbee, D. E., & Hoes, A. W. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.01.010 · Cited by 291
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
Metadata
- Authors
- Agostoni, P., Magini, A., Andreini, D., Contini, M., Apostolo, A., Bussotti, M., Cattadori, G., & Palermo, P.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12-08
- Volume
- 26
- Issue
- 2
- Pages
- 159-164
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2109879469
- Cited by
- 80
- References
- 4
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spironolactone improves lung diffusion in chronic heart failure. https://app.cochat.ai/papers/10.1093/eurheartj/ehi023
- The paper
- Agostoni, P., Magini, A., Andreini, D., Contini, M., Apostolo, A., Bussotti, M., Cattadori, G., & Palermo, P. (2005). Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.